Compounds > 2,3-bis(palmitoyloxy)-2-propyl-1-palmitoylcysteine
Page last updated: 2024-09-04

2,3-bis(palmitoyloxy)-2-propyl-1-palmitoylcysteine and Leishmaniasis, Visceral

2,3-bis(palmitoyloxy)-2-propyl-1-palmitoylcysteine has been researched along with Leishmaniasis, Visceral in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Gupta, S; Sane, SA; Shakya, N; Shankar, S1

Other Studies

1 other study(ies) available for 2,3-bis(palmitoyloxy)-2-propyl-1-palmitoylcysteine and Leishmaniasis, Visceral

ArticleYear
Effect of Pam3Cys induced protection on the therapeutic efficacy of miltefosine against experimental visceral leishmaniasis.
    Peptides, 2011, Volume: 32, Issue:10

    Topics: Animals; Antiprotozoal Agents; Cricetinae; Cysteine; Female; Leishmaniasis, Visceral; Lipoproteins; Male; Mice; Mice, Inbred BALB C; Phosphorylcholine

2011